

## **I. Remarks**

Claims 1-35 and newly added claims 36-52 are currently pending.

### Amendments to the claims:

Claims 1, 2, and 17 have been amended with this response. Claims 1 and 2 have been amended to correct an inadvertent grammatical error in the claims by correcting the phrase "said DNA sequence" to the correct phrase "a DNA sequence" in both claims. Claim 17 has been amended to correct a typographical error. Claim 17 is properly dependent on claim 2, not on claim 12, because SEQ ID NO. 9 comprises a mutation to an SK1 recognition site. As such, these amendments do not add new matter. Applicants respectfully request their entry.

Claims 36-52 have been newly added with this response. Support for newly added claims 36 and 37 can be found throughout the instant specification and particularly at page 4, lines 5-12; page 6, line 25 - page 7, line 1; page 8, line 12 - page 9, line 4; page 23, line 30 - page 24, line 5; page 25, lines 14-21; and page 26, lines 5-27. Support for newly added claims 38 and 39 can be found throughout the instant specification and particularly at paragraphs , and Figures 2 and 3. Support for new claim 38 can be found throughout the instant specification and particularly at page 8, lines 28-32; page 25, lines 14-2; and Figures 7, 8, and 9. Support for new claim 39-49 can be found throughout the instant specification and particularly at page 8, line 32 - page 9, line 4; and Figure 2. Support for new claim 50 can be found throughout the instant specification and particularly at page 26, lines 14-19 and Figure 3. Support for new claims 51 and 52 can be found throughout the instant specification and particularly at page 23, lines 12-17. These newly added claims do not add new matter. Applicants respectfully request their entry.

### Amendments to the drawings:


Applicants respectfully requests entry of the amendment to the drawings as provided in the section titled "Drawing Amendments". They correct the symbols in Figure 7. As such, these amendments do not add new matter.

#### IV. Conclusion

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

3/29/05  
Date

Respectfully submitted,



Jennifer D. Tousignant  
Agent for Applicants  
Registration No. 54,498  
Telephone: (508) 270-2499  
Facsimile: (508) 872-5415

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, Massachusetts 01701-9322

### **III. Drawing Amendments under 37 C.F.R. § 1.121**

Figure 7 of the instant application has been amended. This amendment corrects a typographical error in the Figure where the same symbol was used for two different experimental groups. The figure now correctly differentiates between these two groups by using two distinct symbols, one for each group. As such, these amendments do not add new matter. The amended drawing, Figure 7, is provided as an attachment to this communication labeled "Replacement Sheet". Applicants respectfully replacement of Figure 7 with the enclosed Replacement Sheet.